Schmid, Marianne

[["dc.bibliographiccitation.firstpage","924"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Urology Focus"],["dc.bibliographiccitation.lastpage","936"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Seif Amir Hosseini, Ali"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Uhlig, Johannes"],["dc.date.accessioned","2020-12-10T14:23:51Z"],["dc.date.available","2020-12-10T14:23:51Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.euf.2017.08.007"],["dc.identifier.issn","2405-4569"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72062"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Gender-specific Differences in Recurrence of Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","459"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Braz J Urol"],["dc.bibliographiccitation.lastpage","467"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2021-06-01T10:48:28Z"],["dc.date.available","2021-06-01T10:48:28Z"],["dc.date.issued","2019"],["dc.description.abstract","Purpose: 68Ga-PSMA PET/CT imaging is a promising modality for the staging of recurrent prostate cancer (PCa). Current evidence suggests limited diagnostic value of the 68Ga-PSMA PET/CT in PSA-levels ≤0.3ng/mL. Experimental data have demonstrated an increase in PSMA-expression in PCa metastases by androgen deprivation in vitro. The aim of the current study was to investigate a possible enhancing effect of PSMA with low-dose androgen deprivation in patients with BCR and low PSA-levels. Materials and Methods: Five patients with PCa and BCR, following radical prostatectomy, underwent 68Ga-PSMA PET/CT. A consecutive 68Ga-PSMA PET/CT was performed 6 to 11 days after injection of 80mg of Degarelix (Firmagon®). We recorded PSA and testosterone serum-levels and changes of PSMA-uptake in 68Ga-PSMA PET/CT images. Results: Median PSA prior 68Ga-PSMA PET/CT was 0.27ng/mL. All patients had a decrease in testosterone serum levels from median 2.95μg/l to 0.16μg/l following Degarelix injection. We observed an increase in the standardized uptake value (SUV) in PSMA-positive lymphogenous and osseous lesions in two patients following androgen deprivation. In another two patients, no PSMA positive signals were detected in either the first or the second scan. Conclusion: Our preliminary results of this feasibility assessment indicate a possible enhancing effect of PSMA-imaging induced by low-dose ADT. Despite several limitations and the small number of patients, this could be a new approach to improve staging by 68Ga-PSMA PET/CT in PCa patients with BCR after primary therapy. Further prospective studies with larger number of patients are needed to validate our findings."],["dc.identifier.doi","10.1590/s1677-5538.ibju.2018.0305"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85949"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.relation.eissn","1677-6119"],["dc.relation.issn","1677-5538"],["dc.title","Enhancing PSMA-uptake with androgen deprivation therapy – a new way to detect prostate cancer metastases?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2939"],["dc.bibliographiccitation.issue","35"],["dc.bibliographiccitation.journal","Future Oncology"],["dc.bibliographiccitation.lastpage","2948"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Boegemann, Martin"],["dc.contributor.author","Schlack, Katrin"],["dc.contributor.author","Rink, Michael"],["dc.contributor.author","Bernhardt, Stephan"],["dc.contributor.author","Moran, Michael"],["dc.contributor.author","Hubbe, Marcus"],["dc.contributor.author","Bergmann, Lothar"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2021-04-14T08:31:13Z"],["dc.date.available","2021-04-14T08:31:13Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.2217/fon-2020-0548"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83525"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1744-8301"],["dc.relation.issn","1479-6694"],["dc.title","Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Surgery"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2021-04-14T08:27:57Z"],["dc.date.available","2021-04-14T08:27:57Z"],["dc.date.issued","2021"],["dc.description.abstract","Purpose: Several studies have demonstrated an advantage of 68Ga-PSMA-PET/CT as staging modality for detection of prostate cancer (PCa) metastases. Data concerning metastatic manifestation and impact on PCa development of mesorectal lymph nodes (MLN) is limited. Our investigation describes MLN metastases as index lesion in 68Ga-PSMA PET/CT imaging for recurrent PCa. Methods: Twelve PCa patients with biochemical recurrence (BCR) after primary therapy who prospectively underwent a baseline 68Ga-PSMA-PET/CT initially showed MLN metastases. Eight of these patients received a follow-up 68Ga-PSMA-PET/CT to evaluate treatment response and further evolution. Prostate-specific antigen (PSA)-levels, changes in PSMA-uptake of MLN metastases and further 68Ga-PSMA PET/CT findings were recorded. Results: Median PSA at the first 68Ga-PSMA-PET/CT was 5.39 ng/ml. In all patients therapeutic management changed after the first 68Ga-PSMA-PET/CT. Androgen deprivation therapy (ADT) was initiated in seven of eight patients, one patient restarted initial ADT. Three patients additionally received salvage radiation therapy (sRT) including the prostatic lodge and docetaxel chemotherapy was started in one case. At follow-up, a decrease of PSA-level was detected in all patients (median 2.05 ng/ml) after median 10 months. In six of eight patients we observed a decrease or complete regress of PSMA-uptake in MLN in the follow-up 68Ga-PSMA-PET/CT. Conclusion: MLN metastases detected by 68Ga-PSMA-PET/CT seem to be a relevant localization of tumor manifestation and may serve as index lesion in the treatment of recurrent PCa. Besides the known oncological benefits of ADT and sRT, in case of sole MLN metastases individualized therapy like salvage lymphadenectomy or RT with a defined radiation field could be options for these patients."],["dc.identifier.doi","10.3389/fsurg.2021.637134"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82459"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","2296-875X"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Future Oncology"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Rink, Michael"],["dc.contributor.author","Moran, Michael"],["dc.contributor.author","Bernhardt, Stephan"],["dc.contributor.author","Hubbe, Marcus"],["dc.contributor.author","Bergmann, Lothar"],["dc.contributor.author","Schlack, Katrin"],["dc.contributor.author","Boegemann, Martin"],["dc.date.accessioned","2021-04-14T08:28:01Z"],["dc.date.available","2021-04-14T08:28:01Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.2217/fon-2020-1020"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82480"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1744-8301"],["dc.relation.issn","1479-6694"],["dc.title","Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]